May 2004
Volume 45, Issue 13
ARVO Annual Meeting Abstract  |   May 2004
Intravitreal triamcinolon in idiopathic juxtafoveal teleangiectasis
Author Affiliations & Notes
  • U. Klaer–Dissars
    Ophthalmology, Univ.–Eye Hospital, Luebeck, Germany
  • M. Mueller
    Ophthalmology, Univ.–Eye Hospital, Luebeck, Germany
  • A. Augustin
    Ophthalmology, Städt. Klinikum, Karlsruhe, Germany
  • U. Schmidt–Erfurth
    Ophthalmology, Univ.–Eye Hospital, Luebeck, Germany
  • Footnotes
    Commercial Relationships  U. Klaer–Dissars, None; M. Mueller, None; A. Augustin, None; U. Schmidt–Erfurth, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 1925. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      U. Klaer–Dissars, M. Mueller, A. Augustin, U. Schmidt–Erfurth; Intravitreal triamcinolon in idiopathic juxtafoveal teleangiectasis . Invest. Ophthalmol. Vis. Sci. 2004;45(13):1925.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: To report the clinical findings of patients treated with intravitreal triamcinolon for type 2A idiopathic juxtafoveal teleangiectasis (IJT). Methods: 10 eyes of 7 consecutive patients presenting with IFT were included in a retrospective, noncomparative, interventional case series. The diagnosis and active leakage were confirmed by fluorescein angiography (FA). 4 mg triamcinolon (kenalog) in 0.1 ml solution was administered via pars plana injection. Documentation included visual acuity testing (Snellen equivalent), fundus photography, FA and optical coherence tomography (OCT) as well as slit–lamp examination and tonometry. The mean follow–up was 7 months (2–12 months). Results: The mean age of the patients was 57.1 years. Baseline snellen equivalent ranged from 20/100 to 20/26 with a mean of 20/50. Before treatment all eyes showed leakage from teleangiectatic vessels by FA. OCT revealed cystic changes in the center of the fovea. 6 weeks after treatment, mean visual acuity was 20/40–2 ranging from 20/200 to 20/30. Three patients had improved by one to three lines and 4 had lost one to three lines. 5 of 10 eyes had a significant reduction in leakage angiographically. At 6 months, mean visual acuity was 20/50, three eyes had lost vision and 7 eyes were stable compared to baseline. Angiographic leakage recurred in 3 of 5 eyes which had shown resolution before. Two eyes received a second injection. In both eyes leakage resolved transiently, but reappeared during follow–up. Visual acuity did not correlate with angiographic leakage activity. Cystic changes in OCT imaging remained unchanged. One patient experienced a transient increase in intraocular pressure up to 35 mmHg which resolved completely under topical medication. Conclusions: Intravitreal administration of triamcinolon may induce resolution of leakage from juxtafoveal teleangiectasis. However, visual acuity is not influenced or may even further decrease despite absence of leakage probably due to persistent cystic changes.

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • retina • vascular occlusion/vascular occlusive disease 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.